Recently in pharma news, Zydus Cadila announced the Ahmadabad-based company has acquired six brands from Merck India, also referred to as MSD outside of the U.S. and Canada, through its wholly-owned subsidiary Zydus Healthcare Ltd. News reports do not indicate how much Zydus Cadila paid for these brands, which fall in the wound management therapy, cardiovascular, and men and women’s health segments.

The brands acquired by Zydus include Axeten, Deca-durabolin, Durabolin, Multiload, Sicastat and Sustanon. According to news reports, Axeten is an antihypertensive. Deca-Durabolin and Durabolin are used in muscle wasting and osteoporosis treatment, and Sustanon is an injectable testosterone replacement therapy prescribed for men. Multiload falls in the women’s contraceptives segment and is an intra-uterine device.

Merck operates its India business through legal subsidiary Organon (India) Private Limited, and has transferred the commercialization and distribution rights for Deca-Durabolin and Durabolin to Zydus as part of the agreement. Assignment of trademarks to Zydus Healthcare Limited in India of all six brands is also part of the deal.

Sharvil Patel, Zydus Healthcare chairman, said the drug maker views the acquisition as a great opportunity to strengthen its core offerings to create growth and value.

REA JET U.S. provides exceptional coding and marking solutions for the pharmaceutical and other industries. We understand the industrial marking challenges that companies in pharma face, and the importance of reliable coding for serialization compliance, track and trace, and more.